nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Zoledronate—CA2—esophageal cancer	0.021	0.673	CrCbGaD
Ibandronate—Risedronate—PTGS2—esophageal cancer	0.0102	0.327	CrCbGaD
Ibandronate—Throat sore—Capecitabine—esophageal cancer	0.00761	0.00797	CcSEcCtD
Ibandronate—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00755	0.0079	CcSEcCtD
Ibandronate—Rash erythematous—Capecitabine—esophageal cancer	0.00717	0.00751	CcSEcCtD
Ibandronate—Body temperature increased—Carboplatin—esophageal cancer	0.00716	0.0075	CcSEcCtD
Ibandronate—Multiple fractures—Methotrexate—esophageal cancer	0.00703	0.00736	CcSEcCtD
Ibandronate—Fracture—Methotrexate—esophageal cancer	0.00703	0.00736	CcSEcCtD
Ibandronate—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00683	0.00715	CcSEcCtD
Ibandronate—Injection site pain—Capecitabine—esophageal cancer	0.00672	0.00704	CcSEcCtD
Ibandronate—Rigors—Capecitabine—esophageal cancer	0.00672	0.00704	CcSEcCtD
Ibandronate—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00612	0.00641	CcSEcCtD
Ibandronate—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00608	0.00636	CcSEcCtD
Ibandronate—Deafness—Cisplatin—esophageal cancer	0.00604	0.00633	CcSEcCtD
Ibandronate—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00603	0.00632	CcSEcCtD
Ibandronate—Hypocalcaemia—Capecitabine—esophageal cancer	0.00599	0.00628	CcSEcCtD
Ibandronate—Renal failure acute—Cisplatin—esophageal cancer	0.00585	0.00613	CcSEcCtD
Ibandronate—Ulcer—Capecitabine—esophageal cancer	0.0058	0.00608	CcSEcCtD
Ibandronate—Cataract—Capecitabine—esophageal cancer	0.00577	0.00604	CcSEcCtD
Ibandronate—Amnesia—Cisplatin—esophageal cancer	0.00575	0.00602	CcSEcCtD
Ibandronate—Bone pain—Capecitabine—esophageal cancer	0.00573	0.006	CcSEcCtD
Ibandronate—Inflammation—Capecitabine—esophageal cancer	0.00566	0.00593	CcSEcCtD
Ibandronate—Injection site reaction—Capecitabine—esophageal cancer	0.00546	0.00571	CcSEcCtD
Ibandronate—Influenza like illness—Capecitabine—esophageal cancer	0.00533	0.00558	CcSEcCtD
Ibandronate—Candida infection—Capecitabine—esophageal cancer	0.00524	0.00549	CcSEcCtD
Ibandronate—Face oedema—Cisplatin—esophageal cancer	0.00522	0.00546	CcSEcCtD
Ibandronate—Blood creatinine increased—Cisplatin—esophageal cancer	0.00506	0.0053	CcSEcCtD
Ibandronate—Oesophagitis—Capecitabine—esophageal cancer	0.00501	0.00525	CcSEcCtD
Ibandronate—Ecchymosis—Capecitabine—esophageal cancer	0.00496	0.0052	CcSEcCtD
Ibandronate—Mouth ulceration—Capecitabine—esophageal cancer	0.00496	0.0052	CcSEcCtD
Ibandronate—Breast disorder—Cisplatin—esophageal cancer	0.00488	0.00511	CcSEcCtD
Ibandronate—Cramp muscle—Cisplatin—esophageal cancer	0.00487	0.0051	CcSEcCtD
Ibandronate—Nasopharyngitis—Cisplatin—esophageal cancer	0.00483	0.00506	CcSEcCtD
Ibandronate—Sleep disorder—Capecitabine—esophageal cancer	0.0046	0.00482	CcSEcCtD
Ibandronate—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00455	0.00477	CcSEcCtD
Ibandronate—Swelling—Capecitabine—esophageal cancer	0.00452	0.00473	CcSEcCtD
Ibandronate—Gastroenteritis—Capecitabine—esophageal cancer	0.00449	0.00471	CcSEcCtD
Ibandronate—Abdominal discomfort—Cisplatin—esophageal cancer	0.00448	0.00469	CcSEcCtD
Ibandronate—Deafness—Capecitabine—esophageal cancer	0.00445	0.00466	CcSEcCtD
Ibandronate—Ulcer—Methotrexate—esophageal cancer	0.00432	0.00452	CcSEcCtD
Ibandronate—Renal failure acute—Capecitabine—esophageal cancer	0.00431	0.00452	CcSEcCtD
Ibandronate—Amnesia—Capecitabine—esophageal cancer	0.00424	0.00444	CcSEcCtD
Ibandronate—Inflammation—Methotrexate—esophageal cancer	0.00421	0.00441	CcSEcCtD
Ibandronate—Thirst—Capecitabine—esophageal cancer	0.00419	0.00438	CcSEcCtD
Ibandronate—Renal impairment—Capecitabine—esophageal cancer	0.00419	0.00438	CcSEcCtD
Ibandronate—Arthritis—Capecitabine—esophageal cancer	0.0041	0.00429	CcSEcCtD
Ibandronate—Renal failure—Cisplatin—esophageal cancer	0.00409	0.00429	CcSEcCtD
Ibandronate—Vaginal inflammation—Methotrexate—esophageal cancer	0.00409	0.00428	CcSEcCtD
Ibandronate—Stomatitis—Cisplatin—esophageal cancer	0.00406	0.00425	CcSEcCtD
Ibandronate—Cystitis noninfective—Methotrexate—esophageal cancer	0.00399	0.00418	CcSEcCtD
Ibandronate—Pain in extremity—Capecitabine—esophageal cancer	0.00398	0.00417	CcSEcCtD
Ibandronate—Osteoarthritis—Capecitabine—esophageal cancer	0.00398	0.00417	CcSEcCtD
Ibandronate—Cystitis—Methotrexate—esophageal cancer	0.00394	0.00413	CcSEcCtD
Ibandronate—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00394	0.00412	CcSEcCtD
Ibandronate—Migraine—Capecitabine—esophageal cancer	0.00392	0.00411	CcSEcCtD
Ibandronate—Vaginal infection—Methotrexate—esophageal cancer	0.00386	0.00404	CcSEcCtD
Ibandronate—Face oedema—Capecitabine—esophageal cancer	0.00385	0.00403	CcSEcCtD
Ibandronate—Urinary retention—Capecitabine—esophageal cancer	0.00379	0.00397	CcSEcCtD
Ibandronate—Blood creatinine increased—Capecitabine—esophageal cancer	0.00373	0.00391	CcSEcCtD
Ibandronate—Ecchymosis—Methotrexate—esophageal cancer	0.00369	0.00387	CcSEcCtD
Ibandronate—Bladder pain—Methotrexate—esophageal cancer	0.00369	0.00387	CcSEcCtD
Ibandronate—Mouth ulceration—Methotrexate—esophageal cancer	0.00369	0.00387	CcSEcCtD
Ibandronate—Urinary tract disorder—Cisplatin—esophageal cancer	0.00369	0.00387	CcSEcCtD
Ibandronate—Connective tissue disorder—Cisplatin—esophageal cancer	0.00367	0.00385	CcSEcCtD
Ibandronate—Urethral disorder—Cisplatin—esophageal cancer	0.00366	0.00384	CcSEcCtD
Ibandronate—Abdominal pain upper—Capecitabine—esophageal cancer	0.00364	0.00381	CcSEcCtD
Ibandronate—Pulmonary oedema—Methotrexate—esophageal cancer	0.00364	0.00381	CcSEcCtD
Ibandronate—Breast disorder—Capecitabine—esophageal cancer	0.0036	0.00377	CcSEcCtD
Ibandronate—Nasopharyngitis—Capecitabine—esophageal cancer	0.00356	0.00373	CcSEcCtD
Ibandronate—Gastritis—Capecitabine—esophageal cancer	0.00353	0.00369	CcSEcCtD
Ibandronate—Eye disorder—Cisplatin—esophageal cancer	0.00349	0.00366	CcSEcCtD
Ibandronate—Cardiac disorder—Cisplatin—esophageal cancer	0.00347	0.00363	CcSEcCtD
Ibandronate—Influenza—Capecitabine—esophageal cancer	0.00344	0.00361	CcSEcCtD
Ibandronate—Dysphagia—Capecitabine—esophageal cancer	0.00344	0.00361	CcSEcCtD
Ibandronate—Asthma—Capecitabine—esophageal cancer	0.00344	0.00361	CcSEcCtD
Ibandronate—Bronchospasm—Capecitabine—esophageal cancer	0.00339	0.00355	CcSEcCtD
Ibandronate—Immune system disorder—Cisplatin—esophageal cancer	0.00338	0.00354	CcSEcCtD
Ibandronate—Mediastinal disorder—Cisplatin—esophageal cancer	0.00337	0.00353	CcSEcCtD
Ibandronate—Bronchitis—Capecitabine—esophageal cancer	0.00331	0.00347	CcSEcCtD
Ibandronate—Alopecia—Cisplatin—esophageal cancer	0.0033	0.00346	CcSEcCtD
Ibandronate—Abdominal discomfort—Capecitabine—esophageal cancer	0.0033	0.00346	CcSEcCtD
Ibandronate—Malnutrition—Cisplatin—esophageal cancer	0.00325	0.00341	CcSEcCtD
Ibandronate—Erythema—Cisplatin—esophageal cancer	0.00325	0.00341	CcSEcCtD
Ibandronate—Renal failure acute—Methotrexate—esophageal cancer	0.00321	0.00336	CcSEcCtD
Ibandronate—Flatulence—Cisplatin—esophageal cancer	0.00321	0.00336	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0032	0.00335	CcSEcCtD
Ibandronate—Muscle spasms—Cisplatin—esophageal cancer	0.00313	0.00328	CcSEcCtD
Ibandronate—Weight decreased—Capecitabine—esophageal cancer	0.00311	0.00326	CcSEcCtD
Ibandronate—Pneumonia—Capecitabine—esophageal cancer	0.00309	0.00323	CcSEcCtD
Ibandronate—Infestation NOS—Capecitabine—esophageal cancer	0.00307	0.00322	CcSEcCtD
Ibandronate—Infestation—Capecitabine—esophageal cancer	0.00307	0.00322	CcSEcCtD
Ibandronate—Depression—Capecitabine—esophageal cancer	0.00306	0.00321	CcSEcCtD
Ibandronate—Ill-defined disorder—Cisplatin—esophageal cancer	0.00302	0.00316	CcSEcCtD
Ibandronate—Renal failure—Capecitabine—esophageal cancer	0.00302	0.00316	CcSEcCtD
Ibandronate—Anaemia—Cisplatin—esophageal cancer	0.00301	0.00315	CcSEcCtD
Ibandronate—Stomatitis—Capecitabine—esophageal cancer	0.00299	0.00313	CcSEcCtD
Ibandronate—Urinary tract infection—Capecitabine—esophageal cancer	0.00298	0.00313	CcSEcCtD
Ibandronate—Osteoarthritis—Methotrexate—esophageal cancer	0.00297	0.00311	CcSEcCtD
Ibandronate—Malaise—Cisplatin—esophageal cancer	0.00293	0.00307	CcSEcCtD
Ibandronate—FDPS—bronchus—esophageal cancer	0.00293	0.211	CbGeAlD
Ibandronate—Hepatobiliary disease—Capecitabine—esophageal cancer	0.0029	0.00304	CcSEcCtD
Ibandronate—FDPS—smooth muscle tissue—esophageal cancer	0.00286	0.207	CbGeAlD
Ibandronate—Myalgia—Cisplatin—esophageal cancer	0.00277	0.0029	CcSEcCtD
Ibandronate—Haemoglobin—Capecitabine—esophageal cancer	0.00277	0.0029	CcSEcCtD
Ibandronate—Anxiety—Cisplatin—esophageal cancer	0.00276	0.00289	CcSEcCtD
Ibandronate—Haemorrhage—Capecitabine—esophageal cancer	0.00276	0.00289	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00275	0.00288	CcSEcCtD
Ibandronate—Discomfort—Cisplatin—esophageal cancer	0.00274	0.00287	CcSEcCtD
Ibandronate—Pharyngitis—Capecitabine—esophageal cancer	0.00274	0.00286	CcSEcCtD
Ibandronate—Urinary tract disorder—Capecitabine—esophageal cancer	0.00272	0.00285	CcSEcCtD
Ibandronate—Oedema peripheral—Capecitabine—esophageal cancer	0.00271	0.00284	CcSEcCtD
Ibandronate—Connective tissue disorder—Capecitabine—esophageal cancer	0.00271	0.00284	CcSEcCtD
Ibandronate—Urethral disorder—Capecitabine—esophageal cancer	0.0027	0.00283	CcSEcCtD
Ibandronate—Breast disorder—Methotrexate—esophageal cancer	0.00268	0.00281	CcSEcCtD
Ibandronate—Anaphylactic shock—Cisplatin—esophageal cancer	0.00266	0.00278	CcSEcCtD
Ibandronate—Infection—Cisplatin—esophageal cancer	0.00264	0.00276	CcSEcCtD
Ibandronate—FDPS—trachea—esophageal cancer	0.00263	0.19	CbGeAlD
Ibandronate—Nervous system disorder—Cisplatin—esophageal cancer	0.0026	0.00273	CcSEcCtD
Ibandronate—Skin disorder—Cisplatin—esophageal cancer	0.00258	0.0027	CcSEcCtD
Ibandronate—Eye disorder—Capecitabine—esophageal cancer	0.00258	0.0027	CcSEcCtD
Ibandronate—Hyperhidrosis—Cisplatin—esophageal cancer	0.00257	0.00269	CcSEcCtD
Ibandronate—Asthma—Methotrexate—esophageal cancer	0.00256	0.00268	CcSEcCtD
Ibandronate—Cardiac disorder—Capecitabine—esophageal cancer	0.00256	0.00268	CcSEcCtD
Ibandronate—Angiopathy—Capecitabine—esophageal cancer	0.0025	0.00262	CcSEcCtD
Ibandronate—Immune system disorder—Capecitabine—esophageal cancer	0.00249	0.00261	CcSEcCtD
Ibandronate—Mediastinal disorder—Capecitabine—esophageal cancer	0.00248	0.0026	CcSEcCtD
Ibandronate—Chills—Capecitabine—esophageal cancer	0.00247	0.00259	CcSEcCtD
Ibandronate—Abdominal discomfort—Methotrexate—esophageal cancer	0.00246	0.00257	CcSEcCtD
Ibandronate—Alopecia—Capecitabine—esophageal cancer	0.00244	0.00255	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00242	0.00253	CcSEcCtD
Ibandronate—Mental disorder—Capecitabine—esophageal cancer	0.00241	0.00253	CcSEcCtD
Ibandronate—Erythema—Capecitabine—esophageal cancer	0.0024	0.00251	CcSEcCtD
Ibandronate—Malnutrition—Capecitabine—esophageal cancer	0.0024	0.00251	CcSEcCtD
Ibandronate—Paraesthesia—Cisplatin—esophageal cancer	0.00238	0.0025	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00238	0.00249	CcSEcCtD
Ibandronate—Flatulence—Capecitabine—esophageal cancer	0.00236	0.00248	CcSEcCtD
Ibandronate—Dysgeusia—Capecitabine—esophageal cancer	0.00235	0.00246	CcSEcCtD
Ibandronate—Back pain—Capecitabine—esophageal cancer	0.00232	0.00243	CcSEcCtD
Ibandronate—Decreased appetite—Cisplatin—esophageal cancer	0.00231	0.00242	CcSEcCtD
Ibandronate—Muscle spasms—Capecitabine—esophageal cancer	0.00231	0.00242	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—esophageal cancer	0.0023	0.00241	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00229	0.0024	CcSEcCtD
Ibandronate—Infestation—Methotrexate—esophageal cancer	0.00229	0.00239	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—esophageal cancer	0.00229	0.00239	CcSEcCtD
Ibandronate—Depression—Methotrexate—esophageal cancer	0.00228	0.00239	CcSEcCtD
Ibandronate—Pain—Cisplatin—esophageal cancer	0.00227	0.00238	CcSEcCtD
Ibandronate—FDPS—digestive system—esophageal cancer	0.00226	0.163	CbGeAlD
Ibandronate—Renal failure—Methotrexate—esophageal cancer	0.00225	0.00235	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—esophageal cancer	0.00223	0.00233	CcSEcCtD
Ibandronate—Ill-defined disorder—Capecitabine—esophageal cancer	0.00223	0.00233	CcSEcCtD
Ibandronate—Anaemia—Capecitabine—esophageal cancer	0.00222	0.00232	CcSEcCtD
Ibandronate—Sweating—Methotrexate—esophageal cancer	0.00219	0.00229	CcSEcCtD
Ibandronate—Feeling abnormal—Cisplatin—esophageal cancer	0.00219	0.00229	CcSEcCtD
Ibandronate—Malaise—Capecitabine—esophageal cancer	0.00216	0.00227	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00216	0.00226	CcSEcCtD
Ibandronate—Vertigo—Capecitabine—esophageal cancer	0.00216	0.00226	CcSEcCtD
Ibandronate—Palpitations—Capecitabine—esophageal cancer	0.00212	0.00222	CcSEcCtD
Ibandronate—Body temperature increased—Cisplatin—esophageal cancer	0.0021	0.0022	CcSEcCtD
Ibandronate—Hypertension—Capecitabine—esophageal cancer	0.00207	0.00217	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—esophageal cancer	0.00206	0.00216	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—esophageal cancer	0.00205	0.00215	CcSEcCtD
Ibandronate—Arthralgia—Capecitabine—esophageal cancer	0.00204	0.00214	CcSEcCtD
Ibandronate—Myalgia—Capecitabine—esophageal cancer	0.00204	0.00214	CcSEcCtD
Ibandronate—Chest pain—Capecitabine—esophageal cancer	0.00204	0.00214	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—esophageal cancer	0.00204	0.00213	CcSEcCtD
Ibandronate—Anxiety—Capecitabine—esophageal cancer	0.00204	0.00213	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00203	0.00212	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—esophageal cancer	0.00203	0.00212	CcSEcCtD
Ibandronate—Discomfort—Capecitabine—esophageal cancer	0.00202	0.00211	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—esophageal cancer	0.00201	0.00211	CcSEcCtD
Ibandronate—Dry mouth—Capecitabine—esophageal cancer	0.002	0.00209	CcSEcCtD
Ibandronate—Hypersensitivity—Cisplatin—esophageal cancer	0.00196	0.00205	CcSEcCtD
Ibandronate—Infection—Capecitabine—esophageal cancer	0.00195	0.00204	CcSEcCtD
Ibandronate—Shock—Capecitabine—esophageal cancer	0.00193	0.00202	CcSEcCtD
Ibandronate—Nervous system disorder—Capecitabine—esophageal cancer	0.00192	0.00201	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—esophageal cancer	0.00192	0.00201	CcSEcCtD
Ibandronate—Asthenia—Cisplatin—esophageal cancer	0.00191	0.002	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—esophageal cancer	0.0019	0.00199	CcSEcCtD
Ibandronate—Skin disorder—Capecitabine—esophageal cancer	0.0019	0.00199	CcSEcCtD
Ibandronate—Hyperhidrosis—Capecitabine—esophageal cancer	0.00189	0.00198	CcSEcCtD
Ibandronate—FDPS—lung—esophageal cancer	0.00189	0.136	CbGeAlD
Ibandronate—Angiopathy—Methotrexate—esophageal cancer	0.00186	0.00195	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—esophageal cancer	0.00185	0.00194	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—esophageal cancer	0.00185	0.00194	CcSEcCtD
Ibandronate—Chills—Methotrexate—esophageal cancer	0.00184	0.00193	CcSEcCtD
Ibandronate—Diarrhoea—Cisplatin—esophageal cancer	0.00182	0.0019	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—esophageal cancer	0.00181	0.0019	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—esophageal cancer	0.0018	0.00188	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—esophageal cancer	0.00179	0.00187	CcSEcCtD
Ibandronate—Erythema—Methotrexate—esophageal cancer	0.00179	0.00187	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00178	0.00187	CcSEcCtD
Ibandronate—Insomnia—Capecitabine—esophageal cancer	0.00177	0.00185	CcSEcCtD
Ibandronate—Paraesthesia—Capecitabine—esophageal cancer	0.00176	0.00184	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—esophageal cancer	0.00175	0.00183	CcSEcCtD
Ibandronate—Back pain—Methotrexate—esophageal cancer	0.00173	0.00181	CcSEcCtD
Ibandronate—Dyspepsia—Capecitabine—esophageal cancer	0.00172	0.0018	CcSEcCtD
Ibandronate—Decreased appetite—Capecitabine—esophageal cancer	0.0017	0.00178	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00169	0.00177	CcSEcCtD
Ibandronate—Vomiting—Cisplatin—esophageal cancer	0.00169	0.00177	CcSEcCtD
Ibandronate—Fatigue—Capecitabine—esophageal cancer	0.00169	0.00177	CcSEcCtD
Ibandronate—Rash—Cisplatin—esophageal cancer	0.00167	0.00175	CcSEcCtD
Ibandronate—Pain—Capecitabine—esophageal cancer	0.00167	0.00175	CcSEcCtD
Ibandronate—Constipation—Capecitabine—esophageal cancer	0.00167	0.00175	CcSEcCtD
Ibandronate—Dermatitis—Cisplatin—esophageal cancer	0.00167	0.00175	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—esophageal cancer	0.00166	0.00174	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—esophageal cancer	0.00165	0.00173	CcSEcCtD
Ibandronate—Feeling abnormal—Capecitabine—esophageal cancer	0.00161	0.00169	CcSEcCtD
Ibandronate—Malaise—Methotrexate—esophageal cancer	0.00161	0.00169	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—esophageal cancer	0.0016	0.00168	CcSEcCtD
Ibandronate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0016	0.00168	CcSEcCtD
Ibandronate—Nausea—Cisplatin—esophageal cancer	0.00158	0.00165	CcSEcCtD
Ibandronate—Urticaria—Capecitabine—esophageal cancer	0.00156	0.00163	CcSEcCtD
Ibandronate—Abdominal pain—Capecitabine—esophageal cancer	0.00155	0.00162	CcSEcCtD
Ibandronate—Body temperature increased—Capecitabine—esophageal cancer	0.00155	0.00162	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—esophageal cancer	0.00152	0.00159	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—esophageal cancer	0.00152	0.00159	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—esophageal cancer	0.00152	0.00159	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00151	0.00158	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—esophageal cancer	0.0015	0.00157	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—esophageal cancer	0.00146	0.00153	CcSEcCtD
Ibandronate—Infection—Methotrexate—esophageal cancer	0.00145	0.00152	CcSEcCtD
Ibandronate—Hypersensitivity—Capecitabine—esophageal cancer	0.00144	0.00151	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—esophageal cancer	0.00143	0.0015	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—esophageal cancer	0.00142	0.00148	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—esophageal cancer	0.00141	0.00148	CcSEcCtD
Ibandronate—Asthenia—Capecitabine—esophageal cancer	0.0014	0.00147	CcSEcCtD
Ibandronate—Pruritus—Capecitabine—esophageal cancer	0.00139	0.00145	CcSEcCtD
Ibandronate—Diarrhoea—Capecitabine—esophageal cancer	0.00134	0.0014	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00133	0.00139	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—esophageal cancer	0.00132	0.00138	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—esophageal cancer	0.00131	0.00137	CcSEcCtD
Ibandronate—Dizziness—Capecitabine—esophageal cancer	0.00129	0.00136	CcSEcCtD
Ibandronate—FDPS—lymph node—esophageal cancer	0.00129	0.0932	CbGeAlD
Ibandronate—Dyspepsia—Methotrexate—esophageal cancer	0.00128	0.00134	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—esophageal cancer	0.00127	0.00133	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00126	0.00132	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—esophageal cancer	0.00126	0.00132	CcSEcCtD
Ibandronate—Pain—Methotrexate—esophageal cancer	0.00125	0.00131	CcSEcCtD
Ibandronate—Vomiting—Capecitabine—esophageal cancer	0.00124	0.0013	CcSEcCtD
Ibandronate—Rash—Capecitabine—esophageal cancer	0.00123	0.00129	CcSEcCtD
Ibandronate—Dermatitis—Capecitabine—esophageal cancer	0.00123	0.00129	CcSEcCtD
Ibandronate—Headache—Capecitabine—esophageal cancer	0.00123	0.00128	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—esophageal cancer	0.0012	0.00126	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00119	0.00125	CcSEcCtD
Ibandronate—Nausea—Capecitabine—esophageal cancer	0.00116	0.00122	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—esophageal cancer	0.00116	0.00121	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—esophageal cancer	0.00115	0.00121	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—esophageal cancer	0.00115	0.00121	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—esophageal cancer	0.00107	0.00112	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—esophageal cancer	0.00105	0.0011	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—esophageal cancer	0.00103	0.00108	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—esophageal cancer	0.000997	0.00104	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—esophageal cancer	0.000964	0.00101	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—esophageal cancer	0.000927	0.000971	CcSEcCtD
Ibandronate—Rash—Methotrexate—esophageal cancer	0.000919	0.000962	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—esophageal cancer	0.000918	0.000962	CcSEcCtD
Ibandronate—Headache—Methotrexate—esophageal cancer	0.000913	0.000956	CcSEcCtD
Ibandronate—Nausea—Methotrexate—esophageal cancer	0.000866	0.000907	CcSEcCtD
